12-19-05



Approved for use through 07/31/2006. QMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Application Number 10/828,481-Conf. #4860 Filing Date TRANSMITTAL April 20, 2004 First Named Inventor **FORM** Carl H. JUNE et al. Art Unit 1632 (to be used for all correspondence after initial filing) Examiner Name D. T. Nguyen Attorney Docket Number Total Number of Pages in This Submission 5 36119.140US3/AM100528 ENCLOSURES (Check all that apply) After Allowance Communication x | Fee Transmittal Form Drawing(s) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please **Extension of Time Request** Terminal Disclaimer Identify below): **Express Abandonment Request** Request for Refund X Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name WILMER CUTLER-PICKERING HALE AND DORR LLP Signature Printed name Colleen Superko Reg. No. Date 39,850 December 15, 2005

Express Mail Label No. EV621477199US Dated: December 6, 2005

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PE 40	Under th
O' 2015	Fees pursual
DEC , 6 700%	FI
FIENT & THAT MEETS	App

Under the Paperwork Reduction Act of 1995, no person are required to	respond to a collection of inform	nation unless it displays a valid OMB control number	
Effective on 10M0M004	Complete if Known		
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).	Application Number	10/828,481-Conf. #4860	
FFF TRANSMITTAL	Filing Date	April 20, 2004	
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).  FEE TRANSMITTAL  For FY 2005  Applicant claims small entity status. See 37 CFR 1.27  TOTAL AMOUNT OF PAYMENT (\$) 180.00	First Named Inventor	Carl H. JUNE et al.	
FOF FY 2005	Examiner Name	D. T. Nguyen	
Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1632	
TOTAL AMOUNT OF PAYMENT (\$) 180.00	Attorney Docket No.	36119.140US3/AM100528	
METHOD OF PAYMENT (check all that apply)			

METHOD OF PAYMEN	IT (check all th	at apply)						
Check Credit	Card M	oney Order	None	Other (	please identify	y):		
X Deposit Account Dep	osit Account Numbe	n: 08-0219	Deposit Account	Name: Wil	mer Cutler	Pickering Ha	le and Do	r LLP
For the above-ider	ntified deposit a	ccount, the [	Director is he	ebv authorize	d to: (check	all that apply)		
	) indicated bel	•		<u></u>		ated below, ex	cept for th	e filina fee
	additional fee(s		mont of					
	37 CFR 1.16 a		yment or	x Credit	any overpay	ments		
FEE CALCULATION								
1. BASIC FILING, SEARC	H, AND EXAM	INATION FE	ES					
		FEES		CH FEES	EXAMINA	TION FEES		
Application Type	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees P	aid (\$)
Utility	300	150	500	250	200	100		4141
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	0		
2. EXCESS CLAIM FEES								Small Entity
Fee Description							Fee (\$)	Fee (\$)
Each claim over 20 (include	ding Reissues)						50	25
Each independent claim of	•	g Reissues)					200	100
Multiple dependent claims	3						360	180
Total Claims Extra	Claims F	ee (\$)	Fee Paid	(\$)		tiple Depende		
·=	x _	= _			<u>Fee</u>	<u>(\$)</u> <u>F</u>	ee Paid (\$	1
	01-1	(0)	Fac Dair	ı (e)	•			_
Indep. Claims Extra	Claims F	<u>ee (\$)                                    </u>	Fee Paid	(\$)				
3. APPLICATION SIZE FE								
If the specification and d		d 100 sheets	of paper (exc	cluding electr	onically file	d sequence or	computer	
listings under 37 CFR	(1.52(e)), the a	pplication si	ze fee due is	\$250 (\$125 f	or small enti	ity) for each ac	lditional 50	)
sheets or fraction ther	eof. See 35 U			• • •				
	Extra Sheets			ional 50 or frac		<u>Fee (\$)</u>	Fee I	Paid (\$)
		/50	(ro	und <b>up</b> to a who	ole number) x		=	Doid (\$)
4. OTHER FEE(S)	tion \$120 for	(no small o	atitu disaaun	• )			rees	<u>Paid (\$)</u>
Non-English Specification, \$130 fee (no small entity discount)  Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement180.00								
Other (e.g., late filing s	urcharge): 18	oo Subitlis	SIOIT OF ALL II	IIOIIIIAIIOII D	isciosule S	laternent		<u></u>

SUBMITTED BY	A 0.0					
Signature	Willen	Juserho	Registration No. (Attorney/Agent)	39,850	Telephone	(617) 526-6000
Name (Print/Type)		7			Date	December 15, 2005

Express Mail Label No. EV621477199US	Dated: December 16, 2005
--------------------------------------	--------------------------

Docket No.: 36119.140US3/AM100528

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Carl H. JUNE et al.

Application No.: 10/828,481

Confirmation No.: 4860

Filed: April 20, 2004

Art Unit: 1632

For: METHODS FOR TRANSFECTING T CELLS

Examiner: D. T. Nguyen

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: December 15, 2005

Respectfully submitted,

12/21/2005 DTESSEM1 00000024 080219

10828403

01 FC:1806

180.00 DA

Colleen Superko

Registration No.: 39,850

WILMER CUTLER PICKERING HALE AND

DORR LLP

60 State Street

Boston, Massachusetts 02109

(617) 526-6000

Attorney for Applicants

5426907 US1DOCS 5426907v1



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

	Complete if Known				
Application Number	10/828,481 - Conf. #4860				
Filing Date	April 20, 2004				
First Named Inventor	Carl H. JUNE et al.				
Art Unit	1632				
Examiner Name	D. T. Nguyen				
Attorney Docket Number	36119.140US3/AM100528				

	U.S. PATENT DOCUMENTS							
Examiner	04-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*		Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	AA*	US-5,272,082	12-21-1993	Santoli et al.				
	AB*	US-5,399,346	03-21-1995	Anderson et al.				
E	AC*	US-5,443,983	08-22-1995	Ochoa et al.				
	AD*	US-5,733,543	03-31-1998	Nabel et al.				
	AE*	US-5,738,852	04-14-1998	Robinson et al.				
	AF*	US-5,827,642	10-27-1998	Riddell et al.				
	AG*	US-5,858,358	01-12-1999	June et al.				
	AH*	US-6,692,964	02-17-2004	June et al.				
	AI*	US-2004-0087025	05-06-2004	June et al.				

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	ಗ್
	ВА	WO-90/05541	05-31-1990	THE REGENTS OF THE UNIVERSITY OF MICHIGAN		
	BB	WO-94/12196	06-09-1994	TANOX BIOSYSTEMS, INC.		
	BC	WO-94/29436	12-22-1994	THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY		
	BD	WO-95/03408	02-02-1995	DANA-FARBER CANCER INSTITUTE		
	BE	WO-95/33823	12-14-1995	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY		
	BF	WO-95/34320	12-21-1995	REGENTS OF THE UNIVERSITY OF MINNESOTA		
	BG	WO-96/01122	01-18-1996	DANA-FARBER CANCER INSTITUTE		
	ВН	WO-96/02646	02-01-1996	CYTOTHERAPEUTICS, INC.		
	ВІ	WO-96/06942	03-07-1996	MAX-PLANCK- GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered
5412827	=

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/828,481 - Conf. #4860	
11	<b>VEORMATION</b>	1 DI	SCLOSURE	Filing Date	April 20, 2004	
l s	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Carl H. JUNE et al.	
				Art Unit	1632	
(Use as many sheets as necessary)		Examiner Name	D. T. Nguyen			
Sheet	2	of	2	Attorney Docket Number	36119.140US3/AM100528	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Cann et al., "High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression," Oncogene, 3:122-128 (1988)	
	СВ	Coghlan, "Gene Dream Fades Away" New Scientist, 148: 14-15 (1995)	
	CC	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" Science, 270:404-410 (1995)	
	CD	Fauser, "Long-Term Expression of Gene Introduction into Normal Human T-Lymphocytes by Retroviral-Mediated Gene Transfer," Journal of Cellular Biochemistry, 45:353-358 (1991)	
	CE	Finer et al., "kat: A High-Efficiency Retroviral Transduction System for PRimary HUman T Lymphocytes," Blood, 83(1):43-50 (1994)	
	CF	Guba et al., "Interleukin-3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," Clinical Research, 37(4) (1989)	
	CG	Gunzburg et al., "Virus Vector Design in Gene Therapy" Molecular Medicine Today, 410-417 (1995)	
!	СН	Lowenthal et al., "Tumor Necrosis Factor α Induces Proteins that Bind Specifically to kB-like Enhancer Elements and Regulate Interleukin 2 Receptor α-chain Gene Expression in Primary Human T Lymphocytes," PNAS USA, 86:2331-2335 (1989)	
	CI	Mastrangelo et al. "Gene Therapy for Human Cancer: An Essay for Clinicians" Seminars In Oncology, 23(1):4-21 (1996)	
	CJ	Novak et al., "In Vitro Transfection of Fresh Thymocytes and T Cells Shows SUbset-Specific Expression of Viral Promoters," Molecular and Cellular Biology, 12:1515-1527 (1992)	
	CK	Park et al., "Transcriptional Regulation of Interleukin 3 (IL3) in Primary Human T Lymphocytes," Journal of Biological Chemistry, 268(9):6299-6308 (1993)	
	CL	Philip et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," Molecular and Cellur	
	СМ	Tiberghein et al., "Ganciclovir Treatment of Herpes Simplex Thymidine Kinase-Transduced Primary T Lymphocytes: An Approach for Specific In Vivo Donor T-Cell Depletion After Bone Marrow Transplantation?" Blood, 84(4):1333-1341 (1994)	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered
5412827	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.